Propofol
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Propofol: From General Anesthesia to Migraine Disorder
One-Sentence Summary
Propofol is a well-established intravenous general anesthetic/sedative agent, most familiar as an induction and maintenance agent for procedural and general anesthesia. The TxGNN model predicts it may be effective for Migraine Disorder, with 5 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | General anesthesia / procedural sedation (formal indication text not available in evidence pack — see Data Gap DG002) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed formal mechanism-of-action data for propofol is not available in this evidence pack (flagged as Data Gap DG002, High severity). Based on the pharmacology literature underlying the repurposing rationale, propofol is a GABA-A receptor agonist with central nervous system depressant and possible antinociceptive effects. Preclinical (animal) models further show that propofol inhibits cortical spreading depression (CSD) — a core pathophysiological mechanism believed to underlie migraine aura and headache generation. This provides a plausible mechanistic bridge from propofol’s known CNS-depressant/anesthetic action to a potential antimigraine effect.
The connection between the original use (general anesthesia/sedation) and the new indication is supported by real-world clinical observation: at subanesthetic (“low”) doses, propofol has long been used off-label in emergency department settings — particularly in pediatric patients — as an abortive agent for acute and refractory migraine, distinct from its standard anesthetic dosing.
Mechanistically, this is coherent: GABA-A agonism at low doses may dampen central pain signaling and cortical hyperexcitability without inducing full anesthesia, while CSD suppression directly targets a proposed trigger for migraine pain. This dual action — sub-anesthetic sedation plus CSD inhibition — is the biological rationale most consistently cited across the clinical trial and literature evidence below.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01604785 | Phase 2/3 | Completed | 74 | Low-dose propofol as abortive therapy for pediatric migraine in the ED; based on prior retrospective experience suggesting safety and possible superiority to standard treatment. |
| NCT02485418 | NA | Completed | 40 | Prospective study evaluating efficacy, safe dosing limits, and duration of effect of low-dose propofol infusion as an abortive agent in pediatric migraine. |
| NCT02492295 | NA | Terminated | 12 | Low-dose propofol for severe refractory migraine in the ED; stopped early, small sample limits interpretability. |
| NCT03789370 | NA | Unknown | 130 | Compares propofol vs. sevoflurane for anesthesia maintenance and postoperative headache incidence; propofol hypothesized to have a protective effect in migraine patients. |
| NCT02443220 | NA | Completed | 315 | Electroacupuncture analgesia study in cardiac surgery; propofol used only as background anesthetic, not a core study variable. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35402989 | 2022 | RCT | Arch Acad Emerg Med | Double-blind RCT comparing propofol+granisetron vs. propofol+metoclopramide for acute migraine symptom management. |
| 29456086 | 2018 | RCT | J Emerg Med | Prospective RCT: low-dose propofol for pediatric migraine, favorable side-effect profile and potentially shorter ED length of stay. |
| 32705801 | 2020 | RCT (pilot) | Emerg Med Australas | Pilot RCT testing IV propofol at procedural sedation dose vs. standard therapy for initial migraine management in the ED. |
| 35573713 | 2022 | RCT | Arch Acad Emerg Med | RCT comparing sumatriptan+placebo vs. sumatriptan+propofol combination for acute migraine. |
| 31621134 | 2020 | Systematic Review | Acad Emerg Med | Systematic review of propofol’s safety and efficacy as an acute migraine therapy in the ED. |
| 41321235 | 2026 | Review (Guideline) | Headache | AHS 2025 guideline update on parenteral pharmacotherapy for acute migraine treatment in the ED. |
| 32705803 | 2020 | Review | Emerg Med Australas | Editorial/review: “Propofol for migraine: just because we can, should we?” — discusses evidence and appropriateness. |
| 27454834 | 2016 | Cohort | Expert Rev Neurother | Describes the drug profile of sub-anesthetic dose propofol in managing super-refractory migraine headaches. |
| 23872997 | 2013 | Review (BET) | Emerg Med J | Best Evidence Topic review: propofol may be safe and effective for acute migraine treatment. |
| 10759925 | 2000 | Case Report | Headache | Early report describing unique effectiveness of IV propofol in treating intractable migraine at an outpatient headache center. |
US Market Information
Currently no marketing authorization records are available in this evidence pack — propofol is registered as Not Marketed (0 licenses) under this regulatory dataset.
Safety Considerations
Please refer to the package insert for safety information. (No key warnings, contraindications, or drug-interaction data were available in this evidence pack; TFDA label warnings/contraindications are flagged as a Blocking data gap — DG001.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The top prediction (migraine disorder) is supported by one completed Phase 2/3 RCT (NCT01604785) plus multiple additional RCTs and systematic reviews (L2 evidence), and a plausible mechanistic pathway (GABA-A agonism, CSD suppression). However, formal safety labeling data (warnings/contraindications) is missing and flagged as Blocking, so the drug cannot yet proceed to a full safety pre-assessment.
To proceed, the following is needed:
- TFDA-equivalent product label (warnings, contraindications) — resolve Blocking gap DG001
- Confirmed, sourced mechanism-of-action documentation from DrugBank — resolve High-severity gap DG002
- A formal safety monitoring protocol for sub-anesthetic dosing outside standard anesthesia settings (airway/respiratory monitoring given propofol’s sedative-anesthetic class)
- Regulatory pathway assessment, since the product currently holds no marketing authorization in this jurisdiction (0 NDAs, “Not Marketed” status)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.